In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks HONG KONG, Oct. 3, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the Hong Kong Department of Health has approved Biktarvy® (bictegravir 50mg/emtricitabine 200...
from PR Newswire: //https://ift.tt/2zO1dn4
No comments:
Post a Comment